Clinical Trial Update: RC18 in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II Trial [Phase 2]

View source ↗

Summary

RC18 is being studied in relapsing-remitting multiple sclerosis in a Phase II trial. The study status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• RC18 (RC18)

Snippet

Sponsor: RemeGen Co., Ltd. | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 2 | Status: TERMINATED